WHO gives new directives on use of chloroquine for Covid-19 treatment

As the world faces the herculean task of getting solution to novel coronavirus, the World Health Organisation (WHO) said it has suspended the "solidarity trial" of hydroxychloroquine for Covid-19 treatment.

The global health agency announced the decision on Monday, May 25, through its director-general, Tedros Ghebreyesus.

Citing the study carried out and published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or with macrolide, Ghebreyesus in his address said WHO is unable to confirm the effect of chloroquine when used for Covid-19 treatment.

We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19.

"Each of these dru'g regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19,” he said.

It would be recalled that two months ago WHO initiated the "solidarity trial" to evaluate the safety and efficacy of chloroquine and three others dr'ugs and dru'g combinations against the pandemic.

But in its address, Ghebreyesus said that WHO discovered more fatalities were recorded across 400 hospitals in 35 countries where hydroxychloroquine was permitted to use for coronavirus treatment.

Post a Comment